Jakarra J. Jones


Related Content

  • Samford University, Cumberland School of Law, JD, cum laude, Associate Editor, Law Review, 2007
  • Georgia Institute of Technology, BS, Industrial Engineering, President’s Scholar, 2004
  • District of Columbia
  • Georgia
  • Virginia
  • U.S. Court of Appeals for the 4th Circuit

JJ has substantive experience in the energy and electric power industries and utilizes a wide array of first-chair litigation, regulatory, investigations and compliance experience in the healthcare, pharmaceutical and financial services sectors. JJ has acted as lead counsel in countless depositions, hearings, trials, arbitrations, mediation and settlement conferences, and federal court proceedings. JJ represents some of the largest utility and energy clients in the country in state regulatory proceedings and litigation concerning renewable energy tariffs and programs, utility base rates and riders, generation and transmission CPCNs, mergers and acquisitions, and large project construction. JJ’s clients benefit from her broad background in white collar criminal litigation, compliance, e-discovery, antitrust litigation, employment litigation, and mass- and single-plaintiff tort litigation, as well as public-company auditing and financial disclosure and reporting. In supporting clients, JJ particularly enjoys opportunities to leverage her strengths in translating, synthesizing and simplifying complex, technical information; creative problem-solving; and strategic business planning. JJ endeavors to be 100 percent responsive to her clients’ needs and aspires to become an indispensable partner to those she supports.

Before rejoining the firm in 2016, JJ served as an Assistant United States Attorney under now-U.S. Deputy Attorney General Rod Rosenstein, successfully defending the United States in over 100 federal civil cases and investigating and prosecuting healthcare fraud and wage and hour fraud.  As a defense attorney and federal prosecutor, JJ has gained a unique depth and breadth of first-chair internal and external investigation experience, as well as presenting investigation findings to senior corporate executives and the government and negotiating settlements with the government. In private practice, JJ has assisted Fortune 250 pharmaceutical and medical devices companies in several of the most significant False Claims Act and FCPA cases of the past decade.

Jakarra J Jones
T: +1 804 775 1132F: +1 804 698 2054Gateway Plaza
800 East Canal Street
Richmond, VA 23219-3916

Jana Cantrel v. United States (D. Md. 2015). Lead counsel for the United States in this medical malpractice case alleging negligence and negligent/intentional infliction of emotional distress. Obtained complete defense victory in bench trial.

Adote Akwei v. Sylvia Burwell (D. Md. 2016). Lead counsel for U.S. Department of Health and Human Services in this employment discrimination, wrongful termination and harassment case brought under Title VII by National Institutes of Health employee; obtained complete summary judgment in favor of defendant.

Yasmin Atkins v. Sylvia Burwell (D. Md. 2016). Lead counsel for U.S. Department of Health and Human Services in this sexual harassment case brought by government contractor; obtained complete summary judgment in favor of defendant.

Marguerite Edwards v. Thomas Vilsack (D. Md. 2016). Lead counsel for U.S. Department of Agriculture in this case alleging age-based discrimination in violation of ADEA and race-based discrimination in violation of Title VII; obtained complete summary judgment in favor of defendant.

Monica Stitt v. U.S. Dep’t of Education (D. Md. 2015). Lead defense counsel for U.S. in this bankruptcy adversary proceeding where plaintiff sought to obtain student loan discharge; obtained complete defense victory in bench trial; successfully defended against multiple appeals.

Defended pharmaceutical manufacturer against allegations of off-label promotion of drug; resulted in favorable $25 million settlement with DOJ.

Defended Fortune 50 healthcare conglomerate against off-label marketing, misbranding and kickback allegations regarding the drug Risperdal.

Conducted 14-month transnational external investigation of acquisition target (a major Norwegian oil and gas company) into potential FCPA violations, including reviewing all consulting agreements related to target company’s operations in 33 countries.

Conducted internal investigation of Fortune 200 pharmaceutical company as a result of its acquisition of a medical device company, focusing on potential FCPA in operations in Belarus, Russia and Libya; as a result, DOJ declined its official FCPA inquiry.

Conducted internal investigation of Fortune 100 multinational manufacturing conglomerate’s Turkish subsidiary concerning allegations of bid rigging, foreign bribery and other conduct; as a result of company’s significant cooperation throughout the investigation and compliance enhancement efforts, DOJ and SEC dropped their 4-year probe into the company.

Conducted internal investigation of medical devices manufacturer concerning potential FCPA violations in China and South Korea.

Conducted transnational internal FCPA-focused investigation for British medical implants manufacturer pursuant to SEC inquiry into its payments to government-employed physicians in Germany, Poland, Turkey and Greece.

Co-author, Managed Care Quarterly Review: Issue 1, McGuireWoods LLP, September 2017